153 related articles for article (PubMed ID: 27585307)
1. CRISPR/Cas9 Technology Targeting Fas Gene Protects Mice From Concanavalin-A Induced Fulminant Hepatic Failure.
Liang WC; Liang PP; Wong CW; Ng TB; Huang JJ; Zhang JF; Waye MM; Fu WM
J Cell Biochem; 2017 Mar; 118(3):530-536. PubMed ID: 27585307
[TBL] [Abstract][Full Text] [Related]
2. A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis.
Jiang N; Zhang X; Zheng X; Chen D; Siu K; Wang H; Ichim TE; Quan D; McAlister V; Chen G; Min WP
PLoS One; 2012; 7(9):e44138. PubMed ID: 22970170
[TBL] [Abstract][Full Text] [Related]
3. A Novel AKT Activator, SC79, Prevents Acute Hepatic Failure Induced by Fas-Mediated Apoptosis of Hepatocytes.
Liu W; Jing ZT; Wu SX; He Y; Lin YT; Chen WN; Lin XJ; Lin X
Am J Pathol; 2018 May; 188(5):1171-1182. PubMed ID: 29673487
[TBL] [Abstract][Full Text] [Related]
4. Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice.
Xi D; Wang M; Ye H; Luo X; Ning Q
PLoS One; 2013; 8(11):e82330. PubMed ID: 24303082
[TBL] [Abstract][Full Text] [Related]
5. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
6. RNA interference targeting Fas protects mice from fulminant hepatitis.
Song E; Lee SK; Wang J; Ince N; Ouyang N; Min J; Chen J; Shankar P; Lieberman J
Nat Med; 2003 Mar; 9(3):347-51. PubMed ID: 12579197
[TBL] [Abstract][Full Text] [Related]
7. Combination of the clustered regularly interspaced short palindromic repeats (CRISPR)-associated 9 technique with the piggybac transposon system for mouse in utero electroporation to study cortical development.
Cheng M; Jin X; Mu L; Wang F; Li W; Zhong X; Liu X; Shen W; Liu Y; Zhou Y
J Neurosci Res; 2016 Sep; 94(9):814-24. PubMed ID: 27317429
[TBL] [Abstract][Full Text] [Related]
8. Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting.
Zhou J; Wang J; Shen B; Chen L; Su Y; Yang J; Zhang W; Tian X; Huang X
FEBS J; 2014 Apr; 281(7):1717-25. PubMed ID: 24494965
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor.
Kosai K; Matsumoto K; Nagata S; Tsujimoto Y; Nakamura T
Biochem Biophys Res Commun; 1998 Mar; 244(3):683-90. PubMed ID: 9535725
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.
Utaipan T; Otto AC; Gan-Schreier H; Chunglok W; Pathil A; Stremmel W; Chamulitrat W
Shock; 2017 Aug; 48(2):251-259. PubMed ID: 28060213
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-221 regulates FAS-induced fulminant liver failure.
Sharma AD; Narain N; Händel EM; Iken M; Singhal N; Cathomen T; Manns MP; Schöler HR; Ott M; Cantz T
Hepatology; 2011 May; 53(5):1651-61. PubMed ID: 21400558
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-35 Gene-Modified Mesenchymal Stem Cells Protect Concanavalin A-Induced Fulminant Hepatitis by Decreasing the Interferon Gamma Level.
Wang W; Guo H; Li H; Yan Y; Wu C; Wang X; He X; Zhao N
Hum Gene Ther; 2018 Feb; 29(2):234-241. PubMed ID: 29054137
[TBL] [Abstract][Full Text] [Related]
13. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin small interfering RNA protects mice from fulminant hepatitis.
Saito Y; Kon S; Fujiwara Y; Nakayama Y; Kurotaki D; Fukuda N; Kimura C; Kanayama M; Ito K; Diao H; Matsui Y; Komatsu Y; Ohtsuka E; Uede T
Hum Gene Ther; 2007 Dec; 18(12):1205-14. PubMed ID: 17988193
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro disease modeling with CRISPR/Cas9.
Kato T; Takada S
Brief Funct Genomics; 2017 Jan; 16(1):13-24. PubMed ID: 27497066
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of linarin against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure.
Kim SJ; Cho HI; Kim SJ; Park JH; Kim JS; Kim YH; Lee SK; Kwak JH; Lee SM
Eur J Pharmacol; 2014 Sep; 738():66-73. PubMed ID: 24877692
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2].
Guo JW; Xi D; Yan WM; Luo XP; Ning Q
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):691-4. PubMed ID: 19785959
[TBL] [Abstract][Full Text] [Related]
18. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
19. TAT-apoptosis repressor with caspase recruitment domain protein transduction rescues mice from fulminant liver failure.
An J; Harms C; Lättig-Tünnemann G; Sellge G; Mandić AD; Malato Y; Heuser A; Endres M; Trautwein C; Donath S
Hepatology; 2012 Aug; 56(2):715-26. PubMed ID: 22392694
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Cas9: a new and promising player in gene therapy.
Xiao-Jie L; Hui-Ying X; Zun-Ping K; Jin-Lian C; Li-Juan J
J Med Genet; 2015 May; 52(5):289-96. PubMed ID: 25713109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
